Separately, Zacks Investment Research raised shares of Cellectar Biosciences from a sell rating to a hold rating in a report on Wednesday, July 25th.
CLRB stock opened at $2.42 on Tuesday. Cellectar Biosciences has a fifty-two week low of $2.02 and a fifty-two week high of $15.90. The stock has a market capitalization of $11.13 million, a P/E ratio of -0.23 and a beta of 0.63.
Several hedge funds have recently added to or reduced their stakes in the stock. Wexford Capital LP acquired a new stake in shares of Cellectar Biosciences in the 3rd quarter worth about $750,000. Sphera Funds Management LTD. acquired a new stake in shares of Cellectar Biosciences in the 3rd quarter worth about $263,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Cellectar Biosciences in the 3rd quarter worth about $176,000. 11.67% of the stock is currently owned by institutional investors and hedge funds.
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies.
See Also: Why is the conference call important?
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.